Burkholderia and Emerging Pathogens in Cystic Fibrosis

Seminars in Respiratory and Critical Care Medicine

Volumn 24, Issue 6, 2003, Pages 681-692

  LiPuma, John J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Achromobacter (Alcaligenes) xylosoxidans; Burkholderia cepacia; Pandoraea spp.; Ralstonia spp.; Stenotrophomonas maltophilia

Indexed keywords

CARBAPENEM DERIVATIVE; CEFTAZIDIME; CHLORAMPHENICOL; CIPROFLOXACIN; COTRIMOXAZOLE; GATIFLOXACIN; IMIPENEM; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ACHROMOBACTER; ACHROMOBACTER XYLOSOXIDANS; ANTIBIOTIC RESISTANCE; BACTERIAL VIRULENCE; BACTERIUM IDENTIFICATION; BURKHOLDERIA; BURKHOLDERIA CEPACIA; BURKHOLDERIA GLADIOLI; BURKHOLDERIA PSEUDOMALLEI; CYSTIC FIBROSIS; DISEASE ASSOCIATION; ENTEROBACTERIACEAE; GENOTYPE; HUMAN; INCIDENCE; INFECTION CONTROL; NONHUMAN; PRIORITY JOURNAL; RALSTONIA; RESPIRATORY TRACT INFECTION; REVIEW; SPUTUM ANALYSIS; STENOTROPHOMONAS MALTOPHILIA; TAXONOMY;

EID: 0242621134     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-815664     Document Type: Review

References (134)

1. Burkholder WH. Sour skin, a bacterial rot of onion bulbs. Phytopathol 1950;40:115-118
2. Yabuuchi E, Kosako Y, Oyaizu H, et al. Proposal of Burkholderia gen. nov. and transfer of seven species of the genus Pseudomonas homology group II to the new genus, with the type species Burkholderia cepacia (Palleroni and Holmes 1981) comb. nov. Microbiol Immunol 1992;36:1251-1275
3. Coenye T, Vandamme P, Govan JRW, LiPuma JJ. Taxonomy and identification of the Burkholderia cepacia complex. J Clin Microbiol 2001;39:3427-3436
4. Vandamme P, Holmes B, Vancanneyt M, et al. Occurrence of multiple genomovars of Burkholderia cepacia in cystic fibrosis patients and proposal of Burkholderia multivorans sp. nov. Int J Syst Bacteriol 1997;47:1188-1200.
5. Vandamme P, Henry D, Coenye T, et al. Burkholderia anthina sp. nov. and Burkholderia pyrrocinia, two additional Burkholderia cepacia complex bacteria, may confound results of new molecular diagnostic tools. FEMS Immunol Med Microbiol 2002;33:143-149
6. LiPuma JJ, Spilker T, Gill LH, et al. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med 2001;164:92-96
7. Agodi A, Mahenthiralingam E, Barchitta M, et al. Burkholderia cepacia complex infection in Italian patients with cystic fibrosis: prevalence, epidemiology and genomovar status. J Clin Microbiol 2001;39:2891-2896
8. Speert DP, Henry D, Vandamme P, et al. Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg Infect Dis 2002;8:181-187
9. McMenamin JD, Zaccone TM, Coenye T, et al. Misidentification of Burkholderia cepacia in US cystic fibrosis treatment centers: an analysis of 1,051 recent sputum isolates. Chest 2000;117:1661-1665
10. Shreve MR, Butler S, Kaplowitz HJ, et al. Impact of microbiology practice on cumulative prevalence of respiratory tract bacteria in patients with cystic fibrosis. J Clin Microbiol 1999;37:753-757
11. Kiska DL, Kerr A, Jones MC, et al. Accuracy of four commercial systems for identification of Burkholderia cepacia and other gram-negative nonfermenting bacilli recovered from patients with cystic fibrosis. J Clin Microbiol 1996;34:886-891
12. van Pelt C, Verduin CM, Goessens WH, et al. Identification of Burkholderia spp. in the clinical microbiology laboratory: comparison of conventional and molecular methods. J Clin Microbiol 1999;37:2158-2164
13. Shelly DB, Spilker T, Gracely EJ, et al. Utility of commercial systems for identification of Burkholderia cepacia complex from cystic fibrosis sputum culture. J Clin Microbiol 2000;38:3112-3115
14. Brisse S, Stefani S, Verhoef J, et al. Comparative evaluation of the BD Phoenix and VITEK 2 automated instruments for identification of isolates of the Burkholderia cepacia complex. J Clin Microbiol 2002;40:1743-1748
15. LiPuma JJ, Dulaney BJ, McMenamin JD, et al. Development of rRNA-based PCR assays for identification of Burkholderia cepacia complex isolates recovered from cystic fibrosis patients. J Clin Microbiol 1999;37:3167-3170
16. Mahenthiralingam E, Bischof J, Byrne SK, et al. DNA-based diagnostic approaches for identification of Burkholderia cepacia complex, Burkholderia vietnamiensis, Burkholderia multivorans, Burkholderia stabilis, and Burkholderia cepacia genomovars I and III. J Clin Microbiol 2000;38:3165-3173
17. Henry DA, Mahenthiralingam E, Vandamme P, et al. Phenotypic methods for determining genomovar status of the Burkholderia cepacia complex. J Clin Microbiol 2001;39:1073-1078
18. Coenye T, LiPuma JJ. Molecular epidemiology of Burkholderia species. Front Biosci 2003;8:E55-E67
19. LiPuma JJ. Burkholderia cepacia: management issues and new insights. Clin Chest Med 1998;19:473-486
20. Johnson WM, Tyler SD, Rozee KR. Linkage analysis of geographic and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping. J Clin Microbiol 1994;32:924-930
21. Pitt TL, Kaufmann ME, Patel PS, et al. Type characterization and antibiotic susceptibility of Burkholderia (Pseudomonas) cepacia isolates from patients with cystic fibrosis in the United Kingdom and the Republic of Ireland. J Med Microbiol 1996;44:203-210
22. Chen JS, Witzmann KA, Spilker T, et al. Endemicity and inter-city spread of Burkholderia cepacia genomovar III in cystic fibrosis. J Pediatr 2001;139:643-649
23. Liu L, Spilker T, Coenye T, LiPuma JJ. Identification by subtractive hybridization of a novel insertion element specific for two wide spread epidemic Burkholderia cepacia genomovar III strains. J Clin Microbiol 2003;41:2471-2476
24. Sajjan US, Sun L, Goldstein R, Forstner JF. Cable (cbl) type II pili of cystic fibrosis-associated Burkholderia (Pseudomonas) repacia: nucleotide sequence of the rblA major subunit pilin gene and novel morphology of the assembled appendage fibers. J Bacteriol 1995;177:1030-1038
25. Mahenthiralingam E, Simpson DA, Speert DP. Identification and characterization of a novel DNA marker associated with epidemic Burkholderia cepacia strains recovered from patients with cystic fibrosis. J Clin Microbiol 1997;35:808-816
26. Biddick R, Spilker T, Martin A, LiPuma JJ. Evidence of transmission of Burkholderia cepacia, B. multivorans, and B. dolosa among persons with cystic fibrosis. FEMS Microbiol Lett 2003;228:57-62
27. LiPuma JJ. Burkholderia cepacia epidemiology and pathogenesis: implications for infection control. Curr Opin Pulm Med 1998;4:337-341
28. Ledson MJ, Gallagher MJ, Corkill JE, et al. Cross infection between cystic fibrosis patients colonized with Burkholderia cepacia. Thorax 1998;53:432-436
29. Mahenthiralingam E, Vandamme P, Campbell ME, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001;33:1469-1475
30. Bernhardt S, Spilker T, Coffey T, LiPuma JJ. Burkholderia cepacia complex in cystic fibrosis: frequency of strain replacement during chronic infection. Clin Infect Dis 2003;37:780-785
31. Saiman L, Siegel J, et al. Infection control recommendations for patients with cystic fibrosis: microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Infect Control Hosp Epidemiol 2003;24(suppl):S1-S53
32. Hutchison ML, Govan JR. Pathogenicity of microbes associated with cystic fibrosis. Microbes Infect 1999;1:1005-1014
33. Speert DP, Bond M, Woodman RC, Curnutte JT. Infection with Pseudomonas cepacia in chronic granulomatous disease: role of nonoxidative killing by neutrophils in host defense. J Infect Dis 1994;170:1524-1531
34. Saini LS, Galsworthy SB, John MA, Valvano MA. Intracellular survival of Burkholderia cepacia complex isolates in the presence of macrophage cell activation. Microbiol 1999;145:3465-3475
35. Chiu C-H, Ostry A, Speert DP. Invasion of murine respiratory epithelial cells in vivo by Burkholderia cepacia. J Med Microbiol 2001;50:594-601
36. Huber B, Riedel K, Hentzer M, et al. The cep quorum-sensing system of Burkholderia cepacia H111 controls biofilm formation and swarming motility. Microbiol 2001;147:2517-2528
37. Riedel K, Hentzer M, Geisenberger O, et al. N-acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiol 2001;147:3249-3262
38. Lewenza S, Conway B, Greenberg EP, Sokol PA. Quorum sensing in Burkholderia cepacia: identification of the LuxRI homologs CepRI. J Bacteriol 1999;181:748-756
39. Lewin LO, Byard PJ, Davis PB. Effect of Pseudomonas cepacia colonization on survival and pulmonary function of cystic fibrosis patients. J Clin Epidemiol 1990;43:125-131
40. McCloskey M, McCaughan J, Redmond AOB, Elborn JS. Clinical outcome after acquisition of Burkholderia cepacia in patients with cystic fibrosis. Irish J Med Sci 2001;170:28-31
41. Whiteford ML, Wilkinson JD, McColl JH, et al. Outcome of Burkholderia (Pseudomonas) cepacia colonization in children with cystic fibrosis following a hospital outbreak. Thorax 1995;50:1194-1198
42. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996;143:1007-1017
43. Liou TG, Adler FR, FitzSimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-352
44. Isles A, Maclusky I, Corey M, et al. Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr 1984;104:206-210
45. DeSoyza A, McDowell A, Archer L, et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet 2001;358:1780-1781
46. Aris RM, Routh J, LiPuma JJ, et al. Burkholderia cepacia complex in cystic fibrosis patients after lung transplantation: survival linked to genomovar type. Am J Respir Crit Care Med 2001;164:2102-2106
47. Cox AD, Wilkinson SG. Ionizing groups in lipopolysaccharides of Pseudomonas cepacia in relation to antibiotic resistance. Mol Microbiol 1991;5:641-646
48. Chiesa C, Labrozzi PH, Aronoff SC. Decreased baseline beta-lactamase production and inducibility associated with increased piperacillin susceptibility of Pseudomonas cepacia isolated from children with cystic fibrosis. Pediatr Res 1986;20:1174-1177
49. Burns JL, Lien DM, Hedin LA. Isolation and characterization of dihydrofolate reductase from trimethoprim-susceptible and trimethoprim-resistant Pseudomonas cepacia. Antimicrob Agents Chemother 1989;33:1247-1251
50. Burns JL, Wadsworth CD, Barry JJ, Goodall CP. Nucleotide sequence analysis of a gene from Burkholderia (Pseudomonas) cepacia encoding an outer membrane lipoprotein involved in multiple antibiotic resistance. Antimicrob Agents Chemother 1996;40:307-313
51. Aaron SD, Ferris W, Henry DA, et al. Multiple combination bactericidal antiobiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000;161:1206-1212
52. Christenson JC, Welch DF, Mukwaya G, et al. Recovery of Pseudomonas gladioli from respiratory tract specimens of patients with cystic fibrosis. J Clin Microbiol 1989;27:270-273
53. Barker PM, Wood RE, Gilligan PH. Lung infection with Burkholderia gladioli in a child with cystic fibrosis: acute clinical and spirometric deterioration. Pediatr Pulmonol 1997;23:123-125
54. Jones AM, Dodd ME, Webb AK. Burkholderia cepacia: current clinical issues, environmental controversies and ethical dilemmas. Eur Respir J 2001;17:295-301
55. Khan SU, Gordon SM, Stillwell PC, et al. Empyema and bloodstream infection caused by Burkholderia gladioli in a patient with cystic fibrosis after lung transplantation. Pediatr Infect Dis J 1996;15:637-639
56. Kanj SS, Tapson V, Davis RD, et al. Infections in patients with cystic fibrosis following lung transplantation. Chest 1997;112:924-930
57. Wilsher ML, Kolbe J, Morris AJ, Welch DF. Nosocomial acquisition of Burkholderia gladioli in patients with cystic fibrosis. Am J Respir Crit Care Med 1997;155:1436-1440
58. Clode FE, Metherell LA, Pitt TL. Nosocomial acquisition of Burkholderia gladioli in patients with cystic fibrosis. Am J Respir Crit Care Med 1999;160:374-375
59. Whitby PW, Pope LC, Carter KB, et al. Species specific PCR as a tool for the identification of Burkholderia gladioli. J Clin Microbiol 2000;38:282-285
60. Chaowagul W, White NJ, Dance DA, et al. Melioidosis: a major cause of community-acquired septicemia in northeastern Thailand. J Infect Dis 1999;159:990-999
61. Smith CJ. Human melioidosis: an emerging medical problem. Mircen J 1987;3:343-366
62. Mays EE, Ricketts EA. Melioldosis: recrudescence associated with bronchogenic carcinoma twenty-six years following initial geographic exposure. Chest 1975;68:261-263
63. Dance DA. Melioidosis. Curr Opin Infect Dis 2002;15:127-132
64. Leclarasamee A, Bovornkitti S. Melioidosis: review and update. Rev Infect Dis 1989;11:413-425
65. Dance DA, Smith MD, Aucken HM, Pitt TL. Imported melioidosis in England and Wales. Lancet 1999;353:208
66. Schulin T, Steinmetz I. Chronic melioidosis in a patient with cystic fibrosis. J Clin Microbiol 2001;39:1676-1677
67. Visca P, Cazzola G, Petrucca A, Braggion C. Travel-associated Burkholderia pseudomallei infection (melioidosis) in a patient with cystic fibrosis: a case report. Clin Infect Dis 2001;32:E15-E16
68. Holland DJ, Wesley A, Drinkovic D, Currie BJ. Cystic fibrosis and Burkholderia pseudomallei infection: an emerging problem? Clin Infect Dis 2002;35:e138-e140
69. Swings J, De Vos P, Van den Mooter M, De Ley J. Transfer of Pseudomonas maltophilia Hugh 1981 to the genus Xanthomonas as Xanthomonas maltophilia (Hugh 1981) comb. nov. Int J Syst Bacteriol 1983;33:409-413
70. Palleroni NJ, Bradbury JF. Stenotrophomonas, a new bacterial genus for Xanthomonas maltophilia (Hugh 1980) Swings et al. 1983. Int J Syst Bacteriol 1993;43:606-609
71. Burdge DR, Noble MA, Campbell ME, et al. Xanthomonas maltophilia misidentified as Pseudomonas cepacia in cultures of sputum from patients with cystic fibrosis: a diagnostic pitfall with major clinical implications. Clin Infect Dis 1995;20:445-448
72. Whitby PW, Carter KB, Burns JL, et al. Identification and detection of Stenotrophomonas maltophilia by rRNA-directed PCR. J Clin Microbiol 2000;38:4305-4309
73. Khardori N, Elting L, Wong E, et al. Nosocomial infections due to Xanthomonas maltophilia (Pseudomonas maltophilia) in patients with cancer. Rev Infect Dis 1990;12:997-1003
74. Villarino ME, Stevens LE, Schable B, et al. Risk factors for epidemic Xanthomonas maltophilia infection/colonization in intensive care unit patients. Infect Control Hosp Epidemiol 1992;13:201-206
75. Muder RR, Harris AP, Muller S, et al. Bacteremia due to Stenotrophomonas (Xanthomonas) maltophilia: a prospective, multicenter study of 91 episodes. Clin Infect Dis 1996;22:508-512
76. Alfieri N, Ramotar K, Armstrong P, et al. Two consecutive outbreaks of Stenotrophomonas maltophilia (Xanthomonas maltophilia) in an intensive-care unit defined by restriction fragment-length polymorphism typing. Infect Control Hosp Epidemiol 1999;20:553-556
77. Hanes SD, Demirkan K, Tolley E, et al. Risk factors for late-onset nosocomial pneumonia caused by Stenotrophomonas maltophilia in critically ill trauma patients. Clin Infect Dis 2002;35:228-235
78. Spencer RC. The emergence of epidemic, multiple-antibiotic-resistant Stenotrophomonas (Xanthomanas) maltophilia and Burkholderia (Pseudomonas) cepacia. J Hosp Infect 1995;30(suppl):453-464
79. Denton M, Kerr KG. Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia. Clin Microbiol Rev 1998;11:57-80
80. Sattler CA, Mason EO Jr, Kaplan SL. Nonrespiratory Stenotrophomonas maltophilia infection at a children's hospital. Clin Infect Dis 2000;31:1321-1330
81. Talmaciu I, Varlotta L, Mortensen J, Schidlow DV. Risk factors for emergence of Stenotrophomonas maltophilia in cystic fibrosis. Pediatr Pulmonol 2000;30:10-15
82. Demko CA, Stern RC, Doershuk CF. Stenotrophomonas maltophilia in cystic fibrosis: incidence and prevalence. Pediatr Pulmonol 1998;25:304-308
83. Burns JL, Emerson J, Stapp JR, et al. Microbiology of sputum from patients at cystic fibrosis centers in the United States. Clin Infect Dis 1998;27:158-163
84. Graff GR, Burns JL. Factors affecting the incidence of Stenotrophomonas maltophilia isolation in cystic fibrosis. Chest 2002;121:1754-1760
85. Ballestero S, Virseda I, Escobar H, et al. Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1995;14:728-729
86. Elting LS, Khardori N, Bodey GP, Fainstein V. Nosocomial infection caused by Xanthomonas maltophilia: a case-control study of predisposing factors. Infect Control Hosp Epidemiol 1990;11:134-138
87. Sanyal SC, Mokaddas EM. The increase in carbapenem use and emergence of Stenotrophomonas maltophilia as an important nosocomial pathogen. J Chemother 1999;11:28-33
88. Schaumann R, Stein K, Eckhardt C, et al. Infections caused by Stenotrophomonas maltophilia a prospective study. Infection 2001;29:205-208
89. Carmeli Y, Samore MH. Comparison of treatment with imipenem vs. ceftazidime as a predisposing factor for nosocomial acquisition of Stenotrophomonas maltophilia: a historical cohort study. Clin Infect Dis 1997;24:1131-1134
90. Denton M, Todd NJ, Littlewood JM. Role of anti-pseudomonal antibiotics in the emergence of Stenotrophomonas maltophilia in cystic fibrosis patients. Eur J Clin Microbiol Infect Dis 1996;15:402-405
91. Hauben L, Vauterin L, Moore ER, et al. Genomic diversity of the genus Stenotrophomonas. Int J Syst Bacteriol 1999;49(pt 4):1749-1760
92. Agger WA, Cogbill TH, Busch H, et al. Wounds caused by corn-harvesting machines: an unusual source of infection due to gram-negative bacilli. Rev Infect Dis 1986;8:927-931
93. Klausner JD, Zukerman C, Limaye AP, Corey L. Outbreak of Stenotrophomonas maltophilia bacteremia among patients undergoing bone marrow transplantation: association with faulty replacement of handwashing soap. Infect Control Hosp Epidemiol 1999;20:756-758
94. Weber DJ, Rutala WA, Blanchet CN, et al. Faucet aerators: a source of patient colonization with Stenotrophomonas maltophilia. Am J Infect Control 1999;27:59-63
95. Denton M, Todd NJ, Kerr KG, et al. Molecular epidemiology of Stenotrophomonas maltophilia isolated from clinical specimens from patients with cystic fibrosis and associated environmental samples. J Clin Microbiol 1998;36:1953-1958
96. Krzewinski JW, Nguyen CD, Foster JM, Burns JL. Use of random amplified polymorphic DNA PCR to examine epidemiology of Stenotrophomonas maltophilia and Achromobacter (Alcaligenes) xylosoxidans from patients with cystic fibrosis. J Clin Microbiol 2001;39:3597-3602
97. Senol E, DesJardin J, Stark PC, et al. Attributable mortality of Stenotrophomonas maltophilia bacteremia. Clin Infect Dis 2002;34:1653-1656
98. Gladman G, Connor PJ, Williams RF, David TJ. Controlled study of Pseudomonas cepacia and Pseudomonas maltophilia in cystic fibrosis. Arch Dis Child 1992;67:192-195
99. Karpati F, Malmborg AS, Alfredsson H, et al. Bacterial colonisation with Xanthomonas maltophilia: a retrospective study in a cystic fibrosis patient population. Infection 1994;22:258-263
100. Goss CH, Otto K, Aitken ML, Rubenfeld GD. Detecting Stenotrophomonas maltophilia does not reduce survival of patients with cystic fibrosis. Am J Respir Crit Care Med 2002;166:356-361
101. Schmitz FJ, Verhoef J, Fluit AC. Comparative activities of six different fluoroquinolones against 9,682 clinical bacterial isolates from 20 European university hospitals participating in the European SENTRY surveillance programme. The SENTRY participants group. Int J Antimicrob Agents 1999;12:311-317
102. Ratnalingham RA, Peckham D, Denton M, et al. Stenotrophomonas maltophilia bacteraemia in two patients with cystic fibrosis associated with totally implantable venous access devices. J Infect 2002;44:53-55
103. Krueger TS, Clark EA, Nix DE. In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations. Diagn Microbiol Infect Dis 2001;41:71-78
104. Klinger JD, Thomassen MJ. Occurrence and antimicrobial susceptibility of gram-negative nonfermentative bacilli in cystic fibrosis patients. Diagn Microbiol Infect Dis 1985;3:149-158
105. Vandamme P, Heyndrickx M, Vancanneyt M, et al. Bordetella trematum sp. nov., isolated from wounds and ear infections in humans, and reassessment of Alcaligenes denitrificans Ruger and Tan 1983. Int J Syst Bacteriol 1996;46:849-858
106. Yabuuchi E, Kawamura Y, Kosako Y, Ezaki T. Emendation of genus Achromobacter and Achromobacter xylosoxidans (Yabuuchi and Yano) and proposal of Achromobacter ruhlandii (Packer and Vishniac) comb. nov., Achromobacter piechaudii (Kiredjian et al.) comb. nov., and Achromobacter xylosoxidans subsp. denitrificans (Ruger and Tan) comb. nov. Microbiol Immunol 1998;42:429-438
107. Duggan JM, Goldstein SJ, Chenoweth CE, et al. Achromobacter xylosoxidans bacteremia: report of four cases and review of the literature. Clin Infect Dis 1996;23:569-576
108. Vu-Thien H, Darbord JC, Moissenet D, et al. Investigation of an outbreak of wound infections due to Alcaligenes xylosoxidans transmitted by chlorhexidine in a burns unit. Eur J Clin Microbiol Infect Dis 1998;17:724-726
109. Weitkamp J-H, Tang Y-W, Hass DW, et al. Recurrent Achromobacter xylosoxidans bacteremia associated with persistent lymph node infection in a patient with hyper-immunoglobulin M syndrome. Clin Infect Dis 2000;31:1183-1187
110. Liu L, Coenye T, Burns JL, et al. Ribosomal DNA-directed PCR for identification of Achromobacter (Alcaligenes) xylosoxidans recovered from sputum samples from cystic fibrosis patients. J Clin Microbiol 2002;40:1210-1213
111. Kay SE, Clark RA, White KL, Peel MM. Recurrent Achromobacter piechaudii bacteremia in a patient with hematological malignancy. J Clin Microbiol 2001;39:808-810
112. Tan K, Conway SP, Brownlee KG, et al. Alcaligenes infection in cystic fibrosis. Pediatr Pulmonol 2002;34:101-104
113. Saiman L, Chen Y, Tabibi S, et al. Identification and antimicrobial susceptibility of Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. J Clin Microbiol 2001;39:3942-3945
114. Dunne WM Jr, Maisch S. Epidemiological investigation of infections due to Alcaligenes species in children and patients with cystic fibrosis: use of repetitive-element-sequence polymerase chain reaction. Clin Infect Dis 1995;20:836-841
115. Vu-Thien H, Moissenet D, Valcin M, et al. Molecular epidemiology of Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans in a cystic fibrosis center. Eur J Clin Microbiol Infect Dis 1996;15:876-879
116. Moissenet D, Baculard A, Valcin M, et al. Colonization by Alcaligenes xylosoxidans in children with cystic fibrosis: a retrospective clinical study conducted by means of molecular epidemiological investigation. Clin Infect Dis 1997;24:274-275
117. Peltroche-Llacsahuanga H, Haase G, Kentrup H. Persistent airway colonization with Alcaligenes xylosoxidans in two brothers with cystic fibrosis. Eur J Clin Microbiol Infect Dis 1998;17:132-134
118. Coenye T, Falsen E, Hoste B, et al. Description of Pandoraea gen. nov. with Pandoraea apista sp. nov., Pandoraea pulmonicola sp. nov., Pandoraea pnomenusa sp. nov., Pandoraea sputorum sp. nov. and Pandoraea norimbergensis comb. nov. Int J Syst Evol Microbiol 2000;50:887-899
119. Daneshvar MI, Hollis DG, Steigerwalt AG, et al. Assignment of CDC weak oxidizer group 2 (WO-2) to the genus Pandoraea and characterization of three new Pandoraea genomospecies. J Clin Microbiol 2001;39:1819-1826
120. Stryjewski ME, LiPuma JJ, Messier RH, Reller LB, Alexander BD. Sepsis, multiple organ failure, and death due to Pandoraea pnomenusa infection after lung transplantation. J Clin Microbiol 2003;41:2255-2257
121. Coenye T, Liu L, Vandamme P, LiPuma JJ. Identification of Pandoraea species by 16S ribosomal DNA-based PCR assays. J Clin Microbiol 2001;39:4452-4455
122. Coenye T, LiPuma JJ. Use of the gyrB gene for identification of Pandoreae species. FEMS Microbiol Lett 2002;208:15-19
123. Yabuuchi E, Kosako Y, Yano I, et al. Transfer of two Burkholderia and an Alcaligenes species to Ralstonia gen. nov.: proposal of Ralstonia pickettii (Ralston, Palleroni and Doudoroff 1973) comb. nov., Ralstonia solanacearum (Smith 1896) comb. nov. and Ralstonia eutropha (Davis 1969) comb. nov. Microbiol Immunol 1995;39:897-904
124. Boutros N, Gonullu N, Casetta A, et al. Ralstonia pickettii traced in blood culture bottles. J Clin Microbiol 2002;40:2666-2667
125. Coenye T, Vandamme P, LiPuma JJ. Infection by Ralstonia species in cystic fibrosis patients: identification of R. pickettii and R. mannitolilytica by polymerase chain reaction. Emerg Infect Dis 2002;8:692-696
126. Vandamme P, Goris J, Coenye T, et al. Assignment of centers for disease control group IVc-2 to the genus Ralstonia as Ralstonia paucula sp. nov. Int J Syst Bacteriol 1999;49:663-669
127. Coenye T, Falsen E, Vancanneyt M, et al. Classification of Alcaligenes faecalis-like isolates from the environment and human clinical samples as Ralstonia gilardii sp. nov. Int J Syst Bacteriol 1999;49:405-413
128. Vancechoutte M, De Baere T, Wauters G, et al. One case each of recurrent meningitis and hemoperitoneum infection with Ralstonia mannitolilytica. J Clin Microbiol 2001;39:4588-4590
129. Wauters G, Claeys G, Verschraegen G, et al. Case of catheter sepsis with Ralstonia gilardii in a child with acute lymphoblastic leukemia. J Clin Microbiol 2001;39:4583-4584
130. De Bacre T, Steyaert S, Wauters G, et al. Classification of Ralstonia pickettii biovar 3/'thomasii' strains (Pickett 1994) and of new isolates related to nosocomial recurrent meningitis as Ralstonia mannitolytica sp. nov. Int J Syst Evol Microbiol 2001;51:547-558
131. Coenye T, Goris J, De Vos P, Vandamme P, LiPuma JJ. Classification of Ralstonia pickettii-like isolates from the environment and clinical samples as Ralstonia insidiosa sp. nov. Int J Syst Evol Microbiol 2003;53:1075-1080
132. Coenye T, Vandamme P, LiPuma JJ. Ralstonia respiraculi sp. nov., isolated from the respiratory tract of cystic fibrosis patients. Int J Syst Evol Microbiol 2003;53:1339-1342
133. Coenye T, Goris J, Spilker T, et al. Characterization of unusual bacteria isolated from respiratory secretions of cystic fibrosis patients and description of Inquilinus limosus gen. nov., sp. nov. J Clin Microbiol 2002;40:2062-2069
134. Canton R, Morosini MI, Ballestero S, et al. Lung colonization with Enterobacteriaceae producing extended-spectrum beta-lactamases in cystic fibrosis patients. Pediatr Pulmonol 1997;24:213-217